Ipsen (Pharmaceuticals) Overview
- Year Founded
-
1929
- Status
-
Public
- Employees
-
5,358
- Stock Symbol
-
IPN
- Investments
-
30
- Share Price
-
$119.80
- (As of Thursday Closing)
Ipsen (Pharmaceuticals) General Information
Description
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.
Contact Information
Website
www.ipsen.comCorporate Office
- 65, Quai Georges Gorse
- 92100 Boulogne Billancourt
- France
Corporate Office
- 65, Quai Georges Gorse
- 92100 Boulogne Billancourt
- France
Ipsen (Pharmaceuticals) Timeline
Ipsen (Pharmaceuticals) Stock Performance
As of 12-Jun-2025, Ipsen (Pharmaceuticals)’s stock price is $119.80. Its current market cap is $9.9B with 83M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $119.80 | $118.14 | $101.23 - $136.22 | $9.9B | 83M | 87.2K | $4.52 |
Ipsen (Pharmaceuticals) Financials Summary
As of 31-Dec-2024, Ipsen (Pharmaceuticals) has a trailing 12-month revenue of $3.87B.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 9,014,965 | 9,014,965 | 9,966,269 | 8,455,154 |
| Revenue | 3,867,962 | 3,867,962 | 3,577,774 | 3,318,754 |
| EBITDA | 914,157 | 914,157 | 1,210,842 | 982,221 |
| Net Income | 374,298 | 374,298 | 697,289 | 681,940 |
| Total Assets | 6,700,242 | 6,700,242 | 6,989,333 | 6,021,083 |
| Total Debt | 444,116 | 444,116 | 412,867 | 657,701 |
Ipsen (Pharmaceuticals) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ipsen (Pharmaceuticals) Comparisons
Industry
Financing
Details
Ipsen (Pharmaceuticals) Competitors (43)
One of Ipsen (Pharmaceuticals)’s 43 competitors is AbbVie, a Corporation company based in North Chicago, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| AbbVie | Corporation | North Chicago, IL | ||||
| Recordati | Formerly PE-Backed | Milan, Italy | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Cipla | Corporation | Mumbai, India | ||||
| Novartis | Corporation | Basel, Switzerland |
Ipsen (Pharmaceuticals) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ipsen (Pharmaceuticals) Patents
Ipsen (Pharmaceuticals) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202404021-D0 | Cell-based neurotoxin assay | Pending | 20-Mar-2024 | ||
| GB-202320108-D0 | Biosensor | Pending | 28-Dec-2023 | ||
| GB-202318884-D0 | Formulation | Pending | 11-Dec-2023 | ||
| GB-202307439-D0 | Treatment of a headache disorder with botylinum neurotoxin a | Inactive | 18-May-2023 | ||
| AU-2023351434-A1 | Clostridial neurotoxin for use in a treatment of bladder pain syndrome | Pending | 30-Sep-2022 | A61K38/4893 |
Ipsen (Pharmaceuticals) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ipsen (Pharmaceuticals) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ipsen (Pharmaceuticals) Investments & Acquisitions (30)
Ipsen (Pharmaceuticals)’s most recent deal was a Corporate Asset Purchase with Foreseen Biotech (Rights to Develop, Manufacture and Commercialize FS001) for . The deal was made on 11-Jul-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Foreseen Biotech (Rights to Develop, Manufacture and Commercialize FS001) | 11-Jul-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Ariceum | 18-Apr-2023 | Early Stage VC | Pharmaceuticals | ||
| Albireo | 02-Mar-2023 | Merger/Acquisition | Biotechnology | ||
| Epizyme | 12-Aug-2022 | Merger/Acquisition | Drug Discovery | ||
| Bakx | 18-Nov-2021 | Early Stage VC | Drug Discovery |
Ipsen (Pharmaceuticals) ESG
Risk Overview
Risk Rating
Updated September, 21, 2024
22.76 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Pharmaceuticals
Subindustry
of 419
Rank
Percentile
Ipsen (Pharmaceuticals) Exits (8)
Ipsen (Pharmaceuticals)’s most recent exit was on 16-Feb-2017 from Rhythm Pharmaceuticals. The exit was categorized as with 7 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | 16-Feb-2017 | Completed |
|
||
| Motus Therapeutics | 13-Aug-2015 | Completed |
|
||
| Rhythm Pharmaceuticals | 13-Aug-2015 | Completed |
|
||
| Rhythm Pharmaceuticals | 29-Jul-2013 | Completed |
|
||
| Inserm Transfert | 12-Jan-2012 | Later Stage VC | Completed |
|
Ipsen (Pharmaceuticals) Affiliates
Subsidiaries (8)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Syntaxin | Abingdon, United Kingdom | 2005 | |
| Ipsen Poland | Warsaw, Poland | 2005 | |
| Canbex Therapeutics | London, United Kingdom | 2005 | |
| Ipsen Biopharmaceuticals | Basking Ridge, NJ | 2000 | |
| Sterix | Oxford, United Kingdom | 1998 |
Ipsen (Pharmaceuticals) FAQs
-
When was Ipsen (Pharmaceuticals) founded?
Ipsen (Pharmaceuticals) was founded in 1929.
-
Where is Ipsen (Pharmaceuticals) headquartered?
Ipsen (Pharmaceuticals) is headquartered in Boulogne Billancourt, France.
-
What is the size of Ipsen (Pharmaceuticals)?
Ipsen (Pharmaceuticals) has 5,358 total employees.
-
What industry is Ipsen (Pharmaceuticals) in?
Ipsen (Pharmaceuticals)’s primary industry is Pharmaceuticals.
-
Is Ipsen (Pharmaceuticals) a private or public company?
Ipsen (Pharmaceuticals) is a Public company.
-
What is Ipsen (Pharmaceuticals)’s stock symbol?
The ticker symbol for Ipsen (Pharmaceuticals) is IPN.
-
What is the current stock price of Ipsen (Pharmaceuticals)?
As of 12-Jun-2025 the stock price of Ipsen (Pharmaceuticals) is $119.80.
-
What is the current market cap of Ipsen (Pharmaceuticals)?
The current market capitalization of Ipsen (Pharmaceuticals) is $9.9B.
-
What is Ipsen (Pharmaceuticals)’s current revenue?
The trailing twelve month revenue for Ipsen (Pharmaceuticals) is $3.87B.
-
Who are Ipsen (Pharmaceuticals)’s competitors?
AbbVie, Recordati, GSK, Cipla, and Novartis are some of the 43 competitors of Ipsen (Pharmaceuticals).
-
What is Ipsen (Pharmaceuticals)’s annual earnings per share (EPS)?
Ipsen (Pharmaceuticals)’s EPS for 12 months was $4.52.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
